Several pharmaceutical firms have launched a challenge to the ban in the supreme court
India’s federal government last week banned the manufacture, sale and distribution of 156 fixed dose combination (FDC) drugs for a variety of conditions. This is the government’s second big assault on FDCs – the first ban was announced in 2016 and included 344 combinations – and the list may be expanded in future.